


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound represented by the formula (I):



wherein R^7 and R^{21} , the same or different, represent

- 1) a C_2 to C_{22} alkoxy group which may have a substituent,
- 2) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 3) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) $RC(=Y)-O-$, wherein Y represents an oxygen atom or sulfur atom, and R represents
 - a) a hydrogen atom,
 - b) a C_2 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

- h) a C₁ to C₂₂ alkoxy group which may have a substituent,
- i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
- j) a C₆ to C₁₄ aryloxy group which may have a substituent,
- k) a C₃ to C₁₄ cycloalkyl group which may have a substituent,
- l) a 3-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

6) R^{S1}R^{S2}R^{S3}SiO-, wherein R^{S1}, R^{S2} and R^{S3}, the same or different, represent

- a) a C₁ to C₆ alkyl group or
- b) a C₆ to C₁₄ aryl group,

7) a halogen atom,

8) R^{N1}R^{N2}N-R^M-, wherein R^M represents

- a) a single bond,
- b) -CO-O-,
- c) -SO₂-O-,
- d) -CS-O- or
- e) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group


which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and

R^{N1} and R^{N2}, the same or different, represent

- a) a hydrogen atom,
 - b) a C₁ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) an aliphatic C₂ to C₂₂ acyl group which may have a substituent,
 - e) an aromatic C₇ to C₁₅ acyl group which may have a substituent,
 - f) a C₆ to C₁₄ aryl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - h) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - i) a C₁ to C₂₂ alkylsulfonyl group which may have a substituent,
 - j) a C₆ to C₁₄ arylsulfonyl group which may have a substituent,
 - k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
 - l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or
 - n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 9) R^{N4}SO₂-O-, wherein R^{N4} represents
- a) a C₁ to C₂₂ alkyl group which may have a substituent,
 - b) a C₆ to C₁₄ aryl group which may have a substituent,

- c) a C₁ to C₂₂ alkoxy group which may have a substituent,
 - d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
 - e) a C₆ to C₁₄ aryloxy group which may have a substituent,
 - f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,
 - g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or
 - h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 10) (R^{N5}O)₂PO-O-, wherein R^{N5} represents
- a) a C₁ to C₂₂ alkyl group which may have a substituent,
 - b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - c) a C₆ to C₁₄ aryl group which may have a substituent,
 - d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - e) a C₇ to C₂₂ aralkyl group which may have a substituent or
 - f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 11) (R^{N1}R^{N2}N)₂PO-O-, wherein R^{N1} and R^{N2} are the same as defined above or
- 12) (R^{N1}R^{N2}N)(R^{N5}O)PO-O-, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of these.

2. (Currently Amended) The compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a} , the same or different, represent

- 1) a C_2 to C_{22} alkoxy group which may have a substituent,
- 2) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 3) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 4) $R^aC(=Y^a)-O-$, wherein Y^a represents an oxygen atom or sulfur atom, and R^a represents
 - a) a hydrogen atom,
 - b) a C_2 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C_1 to C_{22} alkoxy group which may have a substituent,

i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
j) a C₆ to C₁₄ aryloxy group which may have a substituent or
k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent,

5) R^{aN1}R^{aN2}N-CO-O-, wherein R^{aN1} and R^{aN2}, the same or different, represent

a) a hydrogen atom,
b) a C₁ to C₂₂ alkyl group which may have a substituent,
c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
d) a C₆ to C₁₄ aryl group which may have a substituent,
e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
f) a C₇ to C₂₂ aralkyl group which may have a substituent,
g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

i) a C₃ to C₁₄ cycloalkyl group which may have a substituent or
j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

6) R^{aN1}R^{aN2}N-SO₂-O-, wherein R^{aN1} and R^{aN2} are the same as defined above,

7) R^{aN1}R^{aN2}N-CS-O-, wherein R^{aN1} and R^{aN2} are the same as defined above,

8) $R^{aN4}SO_2-O-$, wherein R^{aN4} represents

- a) a C_1 to C_{22} alkyl group which may have a substituent,
- b) a C_6 to C_{14} aryl group which may have a substituent,
- c) a C_1 to C_{22} alkoxy group which may have a substituent,
- d) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- e) a C_6 to C_{14} aryloxy group which may have a substituent,
- f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,
- g) a C_7 to C_{22} aralkyloxy group which may have a substituent or
- h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

9) $(R^{aN5}O)_2PO-O-$, wherein R^{aN5} represents

- a) a C_1 to C_{22} alkyl group which may have a substituent,
- b) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
- c) a C_6 to C_{14} aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C_7 to C_{22} aralkyl group which may have a substituent or
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) $(R^{aN1}R^{aN2}N)_2-PO-O-$, wherein R^{aN1} and R^{aN2} are the same as defined above or


11) $(R^{aN1}R^{aN2}N)(R^{aN5}O)PO-O-$, wherein R^{aN1} , R^{aN2} and R^{aN5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

3. (Currently Amended) The compound according to claim 1, wherein R^7 and/or R^{21} represent a C_7 to C_{22} aralkyloxy group which may have a substituent, $RC(=Y)-O-$, wherein Y and R are the same as defined above or $R^{N1}R^{N2}N-R^M$, wherein R^M represents

a) $-CO-O-$ or


b) $-CS-O-$, and R^{N1} and R^{N2} are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

4. (Currently Amended) The compound according to claim 1, wherein R^{N1} and R^{N2} , the same or different, represent a C_1 to C_6 alkyl group or C_6 to C_{14} aryl group, or form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:




or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

5. (Currently Amended) The compound according to claim 2 represented by the formula (I-b):



wherein R^{7b} and R^{21b}, the same or different, represent a C₇ to C₂₂ aralkyloxy group which may have a substituent, or R^b-C(=Y^b)-O-, wherein Y^b represents an oxygen atom or sulfur atom, and R^b, the same or different, represents

- a) a hydrogen atom,
- b) a C₂ to C₆ alkyl group which may have a substituent,
- c) a C₆ to C₁₄ aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C₇ to C₁₀ aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_b represents

- i) $-\text{CHR}^{bN4}-$,
- ii) $-\text{NR}^{bN5}-$,
- iii) $-\text{O}-$,
- iv) $-\text{S}-$,
- v) $-\text{SO}-$ or
- vi) $-\text{SO}_2-$,

R^{bN1} represents

- i) a hydrogen atom or
- ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN2} represents

- i) a hydrogen atom or
- ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN3} and R^{bN4} , the same or different, represent

- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

- iv) a C₆ to C₁₄ aryl group which may have a substituent,
- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C₇ to C₁₀ aralkyl group which may have a substituent,
- vii) a C₃ to C₈ cycloalkyl group which may have a substituent,
- viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) -NR^{bN6}R^{bN7}, wherein R^{bN6} and R^{bN7}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN4} together in combination with the carbon atom to which R^{bN3} and R^{bN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and
R^{bN5} represents
 - i) a hydrogen atom,
 - ii) a C₁ to C₆ alkyl group which may have a substituent,
 - iii) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
 - iv) a C₆ to C₁₄ aryl group which may have a substituent,
 - v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - vi) a C₇ to C₁₀ aralkyl group which may have a substituent,

vii) a C₃ to C₈ cycloalkyl group which may have a substituent,

viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN5} together in combination with the nitrogen atom to which R^{bN3} and R^{bN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_b, n, R^{bN3}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN2} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

C)


X_b, n, R^{bN2}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_b, n, R^{bN1}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN2}

and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN2} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{bN8} and R^{bN9} , the same or different, represent


- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) a C_6 to C_{14} aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- v) a C_7 to C_{10} aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of those.~~

6. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a1}C(=Y^{a1})-O-$, wherein Y^{a1} represents an oxygen atom or sulfur atom, and R^{a1} represents

- 1) a hydrogen atom,

- 2) a C₂ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₀ aryl group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 5) a C₇ to C₁₀ aralkyl group which may have a substituent or
- 6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

7. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a2}C(=Y^{a2})-O-, wherein Y^{a2} represents an oxygen atom or sulfur atom, and R^{a2} represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,

X₁ represents

- 1) -CHR^{aN9}-,
- 2) -NR^{aN10}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or

6) -SO₂-,

R^{aN6} and R^{aN7}, the same or different, represent

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent,

R^{aN8} and R^{aN9}, the same or different, represent

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) -NR^{aN11}R^{aN12}, wherein R^{aN11} and R^{aN12}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or


12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN8} and R^{aN9} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{aN10} represents

- 1) a hydrogen atom,
 - 2) a C_1 to C_6 alkyl group which may have a substituent,
 - 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
 - 4) a C_6 to C_{14} aryl group which may have a substituent,
 - 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - 6) a C_7 to C_{10} aralkyl group which may have a substituent,
 - 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
 - 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
 - 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
 - 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and one substituent selected from the group consisting of R^{aN6} , R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
 - 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and two substituents selected from the group consisting of R^{aN6} , R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
- B) n, X_1 , R^{aN7} , R^{aN9} and R^{aN10} represent the same group as defined above, and R^{aN6} and R^{aN8}

8. (Currently Amended) The compound according to claim ~~[[6]]~~ 7, wherein X₁ represents -NR^{aN10}-, wherein NR^{aN10} is the same as defined above; or a pharmacologically acceptable salt thereof, ~~or a hydrate of those.~~

9. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a3}C(=Y^{a3})-O-, wherein Y^{a3} represents an oxygen atom or sulfur atom, and R^{a3} represents a group of the formula (V):




R^{aN13} represents

- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent, and

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,

3) a pyridinyl group which may have a substituent,
4) a pyrrolidin-1-yl group which may have a substituent,
5) a piperidin-1-yl group which may have a substituent,
6) a morpholin-4-yl group which may have a substituent or
7) a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

10. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a4}CO-O-$, wherein R^{a4} represents a group of the formula (VI):



wherein n_1 and n_2 , the same or different, represent an integer of 0 to 4,

X_2 represents

- 1) $-CHR^{a17}-$,
- 2) $-NR^{a18}-$,
- 3) $-O-$,
- 4) $-S-$,
- 5) $-SO-$ or
- 6) $-SO_2-$,

R^{aN15} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

R^{aN16} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{aN17} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) $-NR^{aN19}R^{aN20}$, wherein R^{aN19} and R^{aN20} , the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or

- 11) a 5-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent, and


R^{aN18} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent or

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

11. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a5}CO-O-$, wherein R^{a5} represents a group of the formula (VII):



wherein n_3 represents 1 or 2,


R^{aN21} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and

R^{aN22} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

12. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a6}CO-O-$, wherein R^{a6} represents a group of the formula (VIII):



wherein n_1 and n_2 , the same or different, represent an integer of 0 to 4,

X_3 represents

- 1) $-CHR^{aN25}-$,
- 2) $-NR^{aN26}-$,
- 3) $-O-$,
- 4) $-S-$,
- 5) $-SO-$ or

6) $-\text{SO}_2-$,

$\text{R}^{\text{aN}23}$ represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent,

$\text{R}^{\text{aN}24}$ represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent,

$\text{R}^{\text{aN}25}$ represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_1 to C_6 alkoxy group which may have a substituent,
- 5) a C_6 to C_{14} aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C_7 to C_{10} aralkyl group which may have a substituent,
- 8) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,

- 11) $-\text{NR}^{\text{aN}27}\text{R}^{\text{aN}28}$, wherein $\text{R}^{\text{aN}27}$ and $\text{R}^{\text{aN}28}$, the same or different, represent a


hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{aN26} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

13. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a7}CO-O-, wherein R^{a7} represents a group of the formula (IX):




wherein n_4 represents an integer of 1 to 3, and

R^{aN29} represents

- 1) an amino group which may have a substituent,
- 2) a pyrrolidin-1-yl group which may have a substituent,
- 3) a piperidin-1-yl group which may have a substituent or
- 4) a morpholin-4-yl group which may have a substituent; or a pharmacologically

acceptable salt thereof, ~~or a hydrate of these.~~

14. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a8}CO-O-$, wherein R^{a8} represents a group of the formula (X):



wherein n_4 represents an integer of 1 to 3,


R^{aN30} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent, and

R^{aN31} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 4) a 3-membered to 8-membered non-aromatic heterocyclic group which may have a substituent,
- 5) a C_6 to C_{14} aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C_7 to C_{10} aralkyl group which may have a substituent,
- 8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

15. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a9}CO-O-$, wherein R^{a9} represents a group of the formula (XI):




wherein n_4 represents an integer of 1 to 3, and

R^{aN32} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 4) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 5) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 6) a pyridyl group which may have a substituent or
- 7) a tetrahydropyranyl group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of those.~~

16. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a10}CO-O-, wherein R^{a10} represents a group of the formula (XII):



wherein m_1 , m_2 , m_3 and m_4 , the same or differently, represent 0 or 1,


n_4 represents an integer of 1 to 3, and

R^{aN33} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,


- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

17. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a11}CO-O-, wherein R^{a11} represents a group of the formula (XIII):




wherein m₅ represents an integer of 1 to 3, and n₅ represents 2 or 3; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

18. (Currently Amended) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a12}CO-O-$, wherein R^{a12} represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;

or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

19. (Currently Amended) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide, (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricos-8,12,14-trien-11-olide and (8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-

yl)carbonyl)oxy-21-phenylcarbamoxyloxy-18,19-epoxytricos-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof, ~~or a hydrate of these.~~

20. (Cancelled)

21. (Currently Amended) A pharmaceutical composition comprising the compound according to claim 1, or a pharmacologically acceptable salt thereof, ~~or a hydrate of these~~ as an active ingredient and a pharmaceutically acceptable carrier.

22-45. (Cancelled)